Men with newly diagnosed metastatic hormone sensitive prostate cancer and a PSA =2 ng/mL with be randomized to either Androgen deprivation therapy (LHRHa) + TAK-700 (ARM 1) or Androgen deprivation therapy (LHRHa) + Bicalutamide (ARM 2, also the standard of care arm). Patients will be followed for 10 years.

Principal Investigator: Jeanny Aragon-Ching, M.D.
Clinical Program: Urological Oncology Program
Primary Sponsor: Southwest Oncology Group (SWOG)
Contact Info: 202-677-6819